01 · Structure
Self-assembling nanovesicle
Hydrocarbon chains of cetylated esters and fatty alcohols align into a birefringent lamellar core, with a surfactant and polar-solvent corona facing the water phase.[1]
Mechanism deep-dive
A single nanovesicle platform takes an active from the skin's surface to the layer where it works, releasing it gradually without breaking the barrier it passes through.
01 Penetration pathway
Cetosome® delivery has four stages. The formulation is applied as a film of intact vesicles. The vesicles move through the stratum corneum along its intercellular lipid route. They break into smaller units that diffuse slowly through the viable epidermis. The active is then released in the layer where it works. Move the slider to follow each stage.
Stage 1 · depth 0 µm
The formulation spreads as a film of intact nanovesicles in a water-rich (≥40%) base. The active is still inside the vesicle, shielded from air and light, and almost none of it touches the skin as free molecules.
Vesicle-bound active; minimal free fraction
Stage 2 · depth ~10–20 µm
Cetylated components are lipid-compatible with the intercellular ceramide–cholesterol–fatty-acid mortar. Vesicles move along this lipid path without permanently disrupting barrier function, which is the main difference from solvent and surfactant penetration enhancers.
Intercellular lipid route; barrier preserved
Stage 3 · depth ~50–100 µm
Cetosomes need not stay intact. They break down into smaller penetration units carrying their cargo, so the active is released gradually from a reservoir rather than all at once, and diffusion continues for hours.
Phased disassembly → gradual release
Stage 4 · depth > 100 µm
The active reaches the layer where it works: keratinocytes, melanocytes, follicles or dermal fibroblasts. For systemic transdermal uses the same platform delivered measurable plasma levels in the patent's animal and volunteer pharmacokinetic examples.
Site of biological activity
Mechanism as described in the granted patent text[1]. For stratum corneum structure see[3]; for molecular-size limits see [4].
02 Release profile
Conventional vehicles release most of their active within the first hour. That early spike crosses the threshold where stinging and erythema begin, and the level then falls below the effective range within hours. A vesicle reservoir releases the same active gradually, holding a moderate, steady level across most of the day.
Move across the chart to read values
| Hour | Conventional | Cetosome® |
|---|---|---|
| 0.5 | 97.5 | 3.3 |
| 1 | 95.1 | 9.5 |
| 2 | 68.7 | 21.1 |
| 4 | 34.2 | 34.4 |
| 8 | 8.4 | 43.2 |
| 12 | 2.1 | 45.3 |
| 16 | 0.5 | 45.9 |
| 20 | 0.1 | 46 |
| 24 | 0 | 22.8 |
03 Core properties
The platform rests on three properties. First, a self-assembling lamellar structure built from cetylated components. Second, dual solubility, so water- and oil-soluble actives share one particle. Third, lipid compatibility with the skin barrier's own ceramide, cholesterol and fatty-acid architecture. Together they allow deeper, gentler and slower delivery than solvent-driven vehicles.
01 · Structure
Hydrocarbon chains of cetylated esters and fatty alcohols align into a birefringent lamellar core, with a surfactant and polar-solvent corona facing the water phase.[1]
02 · Solubility
Polar actives sit in the solvent-rich mantle and non-polar actives in the lamellae. Oil-loaded batches form a second, larger particle population around the oil phase.[1]
03 · Lipid compatibility
The lipid bilayer resembles the stratum corneum's ceramide–cholesterol–fatty-acid mortar[3], so it delivers without the permanent barrier disruption caused by chemical enhancers.[1]
04 Technical specifications
Compared with a conventional cream or serum, the Cetosome® platform reaches more layers and releases over up to 24 hours instead of in one burst. It supports the barrier rather than disrupting it, carries both solubility classes, and has quantified physical specifications: 60–850 nm diameter, −20 to −100 mV claimed charge, and 18–26 months of real-time stability.
| Specification | Conventional | Cetosome® |
|---|---|---|
| Penetration | Surface, limited depth | Multi-layer, follows the intercellular lipid route |
| Release profile | Rapid burst, then decline | Controlled, up to 24 hours |
| Barrier impact | Enhancers often fluidise or extract lipids | Biomimetic; no permanent barrier disruption |
| Active solubility | Hydrophilic or lipophilic per vehicle | Both, on one platform |
| Oxidation protection | Active exposed in film | Shielded within lipid lamellae |
| Particle diameter | Emulsion droplets ~1–20 µm | 60–850 nm measured (claims 30 nm–5 µm) |
| Surface charge (ζ) | Not engineered | −20 to −100 mV claimed; −22 to −55 mV measured |
| pH tolerance | Formulation-specific | Stable across pH 4–10 |
| Real-time stability | Varies | 18–26 months at 25 °C / 65% RH |
| Solvent load | Often ethanol / propylene glycol | Ethanol- and PG-free formulations demonstrated |
Cetosome® specifications from US 9,084,818 B2[1]. Zeta potential measurement depends on conditions; see [7]. For the clinical meaning of size and PDI see[6].
05 Size & morphology
Topical carriers span four orders of magnitude, from 30 nm exosomes to microspheres hundreds of microns across. Cetosomes® occupy the 60–850 nm nanovesicle band, often as two populations: a small, empty-core particle and a larger, oil-cored particle. Particle size matters less than whether the carrier stays stable and releases reproducibly.
Cetosomes are applied in a water-rich base. They move through the stratum corneum along its intercellular lipid route without permanently disrupting barrier function, then break into smaller penetration units that release their cargo gradually through the viable epidermis to the target layer.
Instead of releasing most of the active at once, the vesicle reservoir delivers it over many hours. This keeps concentrations inside the effective range for longer and avoids the early peak associated with stinging and erythema. In the patent's animal pharmacokinetic study (rabbits), drug levels stayed above 2 ng/mL for most of a 24-hour observation period.
Measured particle diameters of 60–850 nm (claims cover 30 nm–5 µm). Zeta potential claimed at −20 to −100 mV, with −22 to −55 mV measured across formulations. Stable at pH 4–10, with real-time stability of 18–26 months at 25 °C / 65% RH. Composition: 4–20% cetylated esters, surfactants, polar solvents and at least 40% water.
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.